CryoLife, Inc. (CRY) PT Raised to $26.00

CryoLife, Inc. (NYSE:CRY) had its target price hoisted by research analysts at Lake Street Capital to $26.00 in a report released on Wednesday. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Lake Street Capital’s target price points to a potential upside of 11.59% from the company’s current price.

Several other equities research analysts also recently commented on CRY. BidaskClub downgraded CryoLife from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Zacks Investment Research downgraded CryoLife from a “buy” rating to a “sell” rating in a report on Wednesday, August 2nd. Finally, Canaccord Genuity restated a “buy” rating and set a $25.00 price objective on shares of CryoLife in a report on Monday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. CryoLife currently has an average rating of “Buy” and a consensus price target of $23.63.

CryoLife (NYSE CRY) opened at 23.30 on Wednesday. CryoLife has a 12 month low of $14.03 and a 12 month high of $24.00. The company has a 50 day moving average price of $21.82 and a 200 day moving average price of $19.17. The firm has a market capitalization of $779.29 million, a price-to-earnings ratio of 70.61 and a beta of 0.92.

CryoLife (NYSE:CRY) last released its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.02. The firm had revenue of $47.80 million during the quarter, compared to the consensus estimate of $47.02 million. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The company’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.13 earnings per share. Analysts anticipate that CryoLife will post $0.43 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/10/11/cryolife-inc-cry-pt-raised-to-26-00.html.

In other news, CEO James P. Mackin sold 125,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total transaction of $2,751,250.00. Following the completion of the sale, the chief executive officer now owns 398,399 shares in the company, valued at $8,768,761.99. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO James P. Mackin sold 43,050 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $22.09, for a total value of $950,974.50. Following the sale, the chief executive officer now owns 398,399 shares of the company’s stock, valued at approximately $8,800,633.91. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 171,050 shares of company stock valued at $3,769,825. Corporate insiders own 6.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its holdings in shares of CryoLife by 16.5% during the first quarter. Wells Fargo & Company MN now owns 31,042 shares of the medical equipment provider’s stock valued at $517,000 after acquiring an additional 4,399 shares in the last quarter. Royce & Associates LP boosted its position in shares of CryoLife by 10.0% during the second quarter. Royce & Associates LP now owns 435,200 shares of the medical equipment provider’s stock valued at $8,682,000 after buying an additional 39,500 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of CryoLife by 4.6% during the first quarter. Ameriprise Financial Inc. now owns 162,996 shares of the medical equipment provider’s stock valued at $2,714,000 after buying an additional 7,228 shares during the last quarter. William Blair Investment Management LLC purchased a new position in shares of CryoLife during the second quarter valued at approximately $4,517,000. Finally, Vanguard Group Inc. boosted its position in shares of CryoLife by 2.9% during the first quarter. Vanguard Group Inc. now owns 1,556,106 shares of the medical equipment provider’s stock valued at $25,909,000 after buying an additional 43,212 shares during the last quarter. Hedge funds and other institutional investors own

Several other equities research analysts also recently commented on CRY. BidaskClub downgraded CryoLife from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Zacks Investment Research downgraded CryoLife from a “buy” rating to a “sell” rating in a report on Wednesday, August 2nd. Finally, Canaccord Genuity restated a “buy” rating and set a $25.00 price objective on shares of CryoLife in a report on Monday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. CryoLife currently has an average rating of “Buy” and a consensus price target of $23.63.

CryoLife (NYSE CRY) opened at 23.30 on Wednesday. CryoLife has a 12 month low of $14.03 and a 12 month high of $24.00. The company has a 50 day moving average price of $21.82 and a 200 day moving average price of $19.17. The firm has a market capitalization of $779.29 million, a price-to-earnings ratio of 70.61 and a beta of 0.92.

CryoLife (NYSE:CRY) last released its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.02. The firm had revenue of $47.80 million during the quarter, compared to the consensus estimate of $47.02 million. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The company’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.13 earnings per share. Analysts anticipate that CryoLife will post $0.43 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/10/11/cryolife-inc-cry-pt-raised-to-26-00.html.

In other news, CEO James P. Mackin sold 125,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total transaction of $2,751,250.00. Following the completion of the sale, the chief executive officer now owns 398,399 shares in the company, valued at $8,768,761.99. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO James P. Mackin sold 43,050 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $22.09, for a total value of $950,974.50. Following the sale, the chief executive officer now owns 398,399 shares of the company’s stock, valued at approximately $8,800,633.91. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 171,050 shares of company stock valued at $3,769,825. Corporate insiders own 6.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its holdings in shares of CryoLife by 16.5% during the first quarter. Wells Fargo & Company MN now owns 31,042 shares of the medical equipment provider’s stock valued at $517,000 after acquiring an additional 4,399 shares in the last quarter. Royce & Associates LP boosted its position in shares of CryoLife by 10.0% during the second quarter. Royce & Associates LP now owns 435,200 shares of the medical equipment provider’s stock valued at $8,682,000 after buying an additional 39,500 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of CryoLife by 4.6% during the first quarter. Ameriprise Financial Inc. now owns 162,996 shares of the medical equipment provider’s stock valued at $2,714,000 after buying an additional 7,228 shares during the last quarter. William Blair Investment Management LLC purchased a new position in shares of CryoLife during the second quarter valued at approximately $4,517,000. Finally, Vanguard Group Inc. boosted its position in shares of CryoLife by 2.9% during the first quarter. Vanguard Group Inc. now owns 1,556,106 shares of the medical equipment provider’s stock valued at $25,909,000 after buying an additional 43,212 shares during the last quarter. Hedge funds and other institutional investors own 68.44% of the company’s stock.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply